Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
48 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Metastatic Biliary Tract Cancer - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Metastatic Biliary Tract Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Biliary Tract Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Biliary Tract Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Biliary Tract Cancer and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Biliary Tract Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Biliary Tract Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Biliary Tract Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Biliary Tract Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Metastatic Biliary Tract Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Metastatic Biliary Tract Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Metastatic Biliary Tract Cancer Overview 6 Therapeutics Development 7 Pipeline Products for Metastatic Biliary Tract Cancer - Overview 7 Pipeline Products for Metastatic Biliary Tract Cancer - Comparative Analysis 8 Metastatic Biliary Tract Cancer - Therapeutics under Development by Companies 9 Metastatic Biliary Tract Cancer - Pipeline Products Glance 10 Clinical Stage Products 10 Metastatic Biliary Tract Cancer - Products under Development by Companies 11 Metastatic Biliary Tract Cancer - Companies Involved in Therapeutics Development 12 AstraZeneca PLC 12 GlaxoSmithKline plc 13 Novartis AG 14 OncoTherapy Science, Inc. 15 Metastatic Biliary Tract Cancer - Therapeutics Assessment 16 Assessment by Monotherapy Products 16 Assessment by Combination Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 23 Drug Profiles 25 (dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 binimetinib - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 OCV-C01 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 selumetinib sulfate - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 trametinib dimethyl sulfoxide - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Metastatic Biliary Tract Cancer - Recent Pipeline Updates 38 Metastatic Biliary Tract Cancer - Discontinued Products 46 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 48 Disclaimer 48
List of Tables Number of Products under Development for Metastatic Biliary Tract Cancer, H2 2014 7 Number of Products under Development for Metastatic Biliary Tract Cancer - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Clinical Stage Development, H2 2014 10 Products under Development by Companies, H2 2014 11 Metastatic Biliary Tract Cancer - Pipeline by AstraZeneca PLC, H2 2014 12 Metastatic Biliary Tract Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 13 Metastatic Biliary Tract Cancer - Pipeline by Novartis AG, H2 2014 14 Metastatic Biliary Tract Cancer - Pipeline by OncoTherapy Science, Inc., H2 2014 15 Assessment by Monotherapy Products, H2 2014 16 Assessment by Combination Products, H2 2014 17 Number of Products by Stage and Target, H2 2014 19 Number of Products by Stage and Mechanism of Action, H2 2014 21 Number of Products by Stage and Route of Administration, H2 2014 22 Number of Products by Stage and Molecule Type, H2 2014 24 Metastatic Biliary Tract Cancer Therapeutics - Recent Pipeline Updates, H2 2014 38 Metastatic Biliary Tract Cancer - Discontinued Products, H2 2014 46
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.